Hypocalcaemia following denosumab in prostate cancer: a clinical review.

CONCLUSIONS: Denosumab treatment in men with metastatic prostate cancer can be associated with life-threatening hypocalcaemia requiring prolonged hospitalization for intravenous calcium treatment. Modifiable risk factors should be corrected before denosumab administration. In men with active osteoblastic metastases, consideration should be given to delay denosumab treatment until underlying disease activity is controlled, and/or be administered with close monitoring and proactive treatment with calcium and calcitriol.
PMID: 32017154 [PubMed - as supplied by publisher]

Source: Clinical Prostate Cancer - February 3, 2020 Category: Cancer & Oncology Authors: Lau LH, Cliff ERS, Wong V, Wong H, Torkamani N, Eer A, Weickhardt A, Grossmann M Tags: Clin Endocrinol (Oxf) Source Type: research